RxDoctor Payments Data

Arthur Weiner, MD

Cardiovascular Disease · Delray Beach, FLNPI 1629002142

Payments from drug & device makers

$915in general payments, 2019–2025

Across 20 payments — averaging $45.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$292
  • Medtronic$208
  • Abiomed$144
  • Novartis$118
  • Abbott$51
  • Shockwave Medical, Inc$49
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$88897%
  • Education$263%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Heartflow, Inc.2$292
Medtronic(2 entities)2$208
Abiomed1$144
Novartis8$118
Abbott2$51
Shockwave Medical, Inc1$49
AstraZeneca2$29
Chiesi USA, Inc.1$13
Pfizer1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$915 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$638,687
Medicare patients
1,707
Services billed
6,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban462$637,832
VyndamaxTafamidis16$588,098
XareltoRivaroxaban115$148,878
EntrestoSacubitril/Valsartan70$118,725
Repatha SureclickEvolocumab96$112,682
Repatha PushtronexEvolocumab28$31,362
FarxigaDapagliflozin Propanediol15$24,063
BrilintaTicagrelor14$17,403
Praluent PenAlirocumab17$11,928
Metoprolol Succinate478$8,597
Atorvastatin Calcium400$4,215
Rosuvastatin Calcium286$4,098
Ranolazine ErRanolazine16$3,637
Valsartan113$3,405
Amiodarone Hcl99$3,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$12$1,225,930478 claims
NovartisEntresto$118$118,72570 claims
AstraZenecaFarxiga, Brilinta$29$41,46529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →